Ona Therapeutics to develop ADC with WuXi’s payload-linker platform

PartnershipWuXiTecan-2Positive

AI Analysis

Summary

WuXi XDC Cayman granted Ona Therapeutics an exclusive global licence to its WuXiTecan-2 payload-linker platform for ADC development. This strategic partnership expands WuXi's ADC platform utilization and provides Ona with access to advanced linker-payload technology.

Importance:6/10

Sentiment:

0.60

ADClicensingpartnershippayload-linker platform

Related Companies

$WXI

Read the original article

Published by Pharmaceutical Technology on September 18, 2026 9:39 AM

Read Original